We are pleased to announce a new collaboration between the MR LATVIA project and Chemestmed, an innovative biotechnology company based in Tartu, Estonia. Chemestmed specializes in drug discovery and development, with a focus on structure-based approaches to identify and optimize bioactive compounds targeting disease-relevant proteins.
As part of this new partnership, Dr. Marta-Lisette Vares from Chemestmed recently visited the Latvian Institute of Organic Synthesis (LIOS) to gain hands-on experience in nuclear magnetic resonance (NMR) spectroscopy. During her visit, she was trained on the use of our high-field NMR instrumentation to investigate protein–ligand interactions — a key method for understanding molecular mechanisms in drug discovery.
This collaboration marks another important step toward strengthening industry–research partnerships in the Baltic region, fostering knowledge exchange and advancing the use of state-of-the-art NMR technologies for biomedical research.
We look forward to a productive and long-term collaboration with Chemestmed, supporting their efforts to accelerate innovative therapeutic development.